By interacting with CD26 on the CD4 ϩ T cell surface and with the AdoR A 2B on the DC surface, ADA triggers a costimulatory signal for human T cells. The aim of this study was to know whether ADA-mediated costimulation plays a role in the differentiation of T cells. The results show that irrespective of its enzymatic activity and dependent on TNF-␣, IFN-␥, and IL-6 action, ADA enhanced the differentiation of CD4 Tregs by a mechanism that seems to be mainly dependent on the enzymatic activity of ADA. Interestingly, an ADA-mediated increase on Teff, memory T cell, and Treg generation occurred, not only in cocultures from healthy individuals but also from HIV-infected patients. These data suggest that ADA is a relevant modulator of CD4 ϩ T cell differentiation, even in cells from immunologically compromised individuals.
Introduction
DCs are relevant APCs for activation of CD4 
Foxp3
ϩ Tregs. Whereas Teffs promote immunity against their cognate Ags, Tregs, by inhibiting function of Teffs, play an important physiological role limiting the effector phase of T cell responses, maintaining self-tolerance, and preventing autoimmunity [1, 2] . After a CD4
ϩ T cell response, reactivated Ag-specific T cells, which are a part of the pool of CD4 ϩ CD45RA -CD45RO ϩ memory T cells [3, 4] , coordinate a faster, stronger, and longer immune response [5, 6] . ADA, an enzyme involved in purine metabolism, catalyzes the hydrolytic deamination of Ado to inosine and ammonia. A congenital defect of ADA causes SCID, which is characterized by the absence of functional lymphocytes in affected individuals [7] . For many years, ADA was considered to be cytosolic, but it has been found on the cell surface of many cells. To date, it has been described that three different surface-anchoring proteins might mediate the binding of ecto-ADA to the cell surface, including the multifunctional protein CD26 and A 1 R and A 2B R [8, 9] . A number of studies have evidenced that ADA, expressed on the cell surface, not only plays enzymatic activity-dependent functions, but also, it can trigger regulatory signals through its extraenzymatic properties [8, 9] .
As a result of its enzymatic activity, ecto-ADA regulates the concentration of Ado available to bind to AdoRs [10] . Surface expression of AdoRs has been described in T cells [11] [12] [13] and in DCs [14 -19] . In human T cells, the major AdoR expressed is the A 2A R [11] [12] [13] , which is coupled with cAMP production. Elevated cAMP levels induce a marked impairment in T cell activation and IL-2 production [20] , which promote anergy and tolerance in Th1 clones [21] . Accordingly, enzymatic activity of ecto-ADA decreases Ado levels available for stimulation of AdoRs expressed on the T cell surface, and this mechanism contributes to immune regulation [10, 22, 23] .
During Ag presentation by DCs, T cell activation is subjected to regulation by several intercellular interactions mediated by surface and soluble molecules that stimulate their receptors expressed on T cells. These regulatory interactions might modulate the activation and differentiation of T cells. In this re-gard, ADA, in a deaminase activity-independent way and by interacting with CD26 on the CD4 ϩ T cell surface and with the A 2B R on the DC surface, triggers a strong costimulatory signal for T cell activation [14] . This ADA-mediated costimulation not only potentiates T cell proliferation but also the secretion of Th1 (IFN-␥) and proinflammatory (IL-6 and TNF-␣) cytokines [8] . Importantly, we have recently described that this ADA-mediated costimulation is attenuated in CD4 ϩ T cells obtained from HIV-infected individuals, which contributes to the immunodeficiency [24] . However, when exogenous ADA is added on a coculture of HIV-pulsed DCs and autologous T cells, it is possible to generate a HIV-specific T cell response. This finding supports the possibility of using exogenous ADA to counteract the HIV-induced attenuation of ADA-mediated costimulation [25] .
To know whether ADA may modulate naïve T cell differentiation, cocultures of naïve CD4
ϩ CD45RA ϩ CD45RO -T cells and autologous superantigen-pulsed DCs were used as a model. ADA not only enhanced Teff generation but also increased memory T cell generation. Interestingly, ADA enhanced the generation of Tregs. The ADA-mediated effects were observed not only in healthy donors but also in immunologically compromised individuals, such as HIV-infected patients. In addition, we analyzed the contribution of IL-6, TNF-␣, IFN-␥, and the deaminase activity to the ADA-mediated effects.
MATERIALS AND METHODS

Sampling and study population
Blood samples were obtained by venipuncture from the antecubital vein. EDTA-treated vacutainers (Becton Dickinson, San Jose, CA, USA) were used as collecting tubes, and every sample was processed immediately after extraction. Fifteen HIV-1-infected patients and 30 healthy control volunteers were included in the study. All individuals gave informed consent. The characteristics of HIV-infected patients are shown in Table 1 .
Antibodies and reagents
The following primary antibodies were used: FITC-conjugated mAb against  HLA-DR, CCR5, CD4, CD14, CD19, CD25, CD45RA, and IgG-␥1 isotypematched control; PE-conjugated mAb against HLA-DR, CXCR4, CD1a,  CD11c, CD14, CD19, CD25, CD40, CD45, CD45RO, CD56 , and IgG-␥1 isotype-matched control, and PerCP-conjugated mAb against CD3, CD4, and IgG-␥1 isotype-matched control from BD Biosciences (Erembodegem-Aalst, Belgium); nonconjugated mouse mAb against CD26 (Ba5), nonconjugated mouse IgG2a control isotype, and PE-conjugated mAb against CD80, CD83, and CD86 (Coulter-Immunotech Diagnostic, Marseille, France); PE-conjugated mAb against CD209 (eBioscience, San Diego, CA, USA); activity-neutralizing mouse mAb against human IL-6, TNF-␣, and IFN-␥ (Bender MedSystems Inc., Burlingame, CA, USA); affinity-purified, nonconjugated goat pAb against A 2B R (N-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA); and nonconjugated rabbit pAb against purified calf ADA [26] . The following secondary pAb were used: FITC-conjugated goat anti-rabbit IgG (Gene Tex, Inc., Irvine, CA, USA), rabbit anti-mouse Igs (Dako, Glostrup Denmark), and rabbit anti-goat IgG (Sigma-Aldrich, St. Louis, MO, USA). All antibodies were used at the concentration range recommended by the supplier. TNF-␣, IL-6, SEA and irrelevant mouse IgGs were purchased from Sigma-Aldrich; IFN-␥ (Actimmune) was from InterMune, Inc. (Brisbane, CA, USA). ADA from calf intestine (Roche Diagnostic Inc., Mannheim, Germany) was desalted by passage through a PD-10 column (Amersham Biosciences, Cerdanyola, Spain), and its enzymatic activity was evaluated for consumption of Ado, measured as decreases in absorbance at 265 nm [27] . To obtain ADA without enzymatic activity, desalted ADA was treated with HgCl 2 , as described previously [28] , and passed again through a PD-10 column to eliminate remaining HgCl 2 . The enzymatic activity of Hg 2ϩ -treated ADA was completely and irreversibly abolished.
Cocultures of monocyte-derived DCs and CD4
؉
CD45RA
؉
CD45RO
-lymphocytes
Human PBMCs were obtained immediately after blood extraction using the standard Ficoll gradient method [29] . Monocytes were obtained as de- 
CD25
-T cells (2ϫ10 5 cells/well) and iDCs (5ϫ10 3 cells/well), pulsed or not with 100 pg/ml SEA for 3.5 h at 37°C in 200 l/well XVIVO-10 medium containing or not 2 M ADA, 20 ng/ml IL-6, 250 U/ml TNF-␣, 1000 U/ml IFN-␥, or a combination of these cytokines. When indicated, cocultures were performed in the presence of 2 M ADA and anti-IL-6 (150 ng/ml), anti-TNF-␣ (1.9 g/ml), anti-IFN-␥ (2 g/ml), or irrelevant mouse IgG1 (2 g/ml) as a negative control. Cocultures were incubated for the indicated times at 37°C in a humid atmosphere of 5% CO 2 .
Immunostaining, quantification of Tregs, and flow cytometry
To analyze expression of cell surface markers, cocultured cells were collected, washed with PBS, resuspended at 2 ϫ 10 6 cells/ml (50 l/tube), and incubated with FITC-, PE-, and/or PerCP-conjugated antibodies (see above) for 30 min at 4°C. Cells were then washed with PBS, fixed with 1% formaldehyde in PBS, and analyzed by flow cytometry. FITC-, PE-, and PerCP-conjugated isotype-matched antibodies were used for negative control. When nonconjugated primary antibodies were used, cells washed with PBS were incubated for 30 min at 4°C with blocking buffer (PBS containing 5% BSA for ADA labeling or PBS containing 10% rabbit serum and 0.1% NaN 3 for CD26 or A 2B R labeling) prior incubation with 10 g/ml N-19, 20 g/ml anti-ADA, 20 g/ml irrelevant rabbit IgG (used as a negative control of anti-ADA), Ba5 (1:10), or mouse IgG2a (1:10) isotype control (used as a negative control of Ba5) for 30 min at 4°C. Cells were washed three times with blocking buffer and stained for flow cytometry analysis with the corresponding secondary antibodies: FITC-conjugated rabbit anti-goat IgG (1:400), FITC-conjugated rabbit anti-mouse IgG (1:20) , and FITC-conjugated goat anti-rabbit IgG. Stained cells were analyzed on a FACSCan flow cytometer (Becton Dickinson). Cells were gated on the basis of forward-and side-scatter parameters, and this gating region was evaluated further for the expression of FL1, FL2, and FL3. To quantify Tregs, Foxp3 was detected using the commercially available human Treg staining kit (eBioscience), following the manufacturer's instructions. Cell samples were analyzed in a FACSCalibur flow cytometer (Becton Dickinson). In all cases, data were analyzed using CellQuest and FlowJo software.
Proliferation assays
T cell proliferation was determined by the CFSE method. Cells (10 7 cells/ ml) were stained with 5 M CFSE, as indicated by the manufacturer's protocol, using the CellTrace CFSE proliferation kit (Molecular Probes, Paisley, UK).
Statistical analysis
Data were analyzed using the GraphPad Prism 5.0 software. Quantitative variables were analyzed using medians and IQRs. The nonparametric Mann Whitney U test for unpaired data or the Wilcoxon signed rank test for paired data was used when comparing two groups. For multiple comparisons, the Kruskal-Wallis test, followed by Dunns post-test, was used. For all the tests used, a two-tailed P value Ͻ0.05 was considered statistically significant. 
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RESULTS
ADA enhanced the switch from the naïve CD45RA
To address whether ADA has an impact over the generation of Teffs, naïve CD4 ϩ CD45RA ϩ CD45RO -T cells were freshly isolated and cocultured with autologous, SEA-pulsed iDCs. As markers of effector phenotype, expression of CD45RO and CD25 was determined by flow cytometry. In the absence of exogenous ADA, the percentage of CD45RO ϩ and CD25 ϩ T cells increased with time, reaching a maximum at Day 7. ADA promoted an increase in the percentage of T cells expressing CD45RO or CD25 with similar kinetics (Fig. 1A and B) . Control assays performed with nonpulsed iDCs did not lead to significant increases of CD45RO or CD25 expression in the absence or presence of ADA ( Fig. 1A and B) . These results indicate that ADA enhanced the TCR-mediated generation of Teffs, but it had no effect by itself. The ADA-mediated, costimulatory effect on CD4 ϩ T cell proliferation is impaired in HIV-infected individuals [24] . Thereby, the question of whether the generation of Teffs is attenuated in cocultures obtained from HIV-infected patients, compared with healthy donors, was investigated. ADA promoted a statistically significant increase of CD45RO and CD25 expression in every tested healthy or HIV-infected donor, showing individual-dependent variability ( Fig. 1C and D) . The ADA-mediated effect was not significantly different when comparing HIV-infected and healthy donors (Fig. 1C and D, insets) , suggesting that ADA is also able to increase generation of the Teff phenotype in these immunologically compromised individuals.
ADA potentiates T cell proliferation in autologous cocultures with Ag-pulsed human iDC or mature DC. Costimulation is not a result of the enzymatic activity but of the interaction of ADA-CD26 complexes on T cells with A 2B R expressed on DCs [14] . Accordingly, in cocultures of naïve CD4 ϩ CD45RA ϩ
CD45RO
-T cells and autologous, SEA-pulsed iDCs, ADA induced an increase in the T cell proliferation that was independent of Ado deamination. Thus, active ADA and ADA-Hg enhanced T cell proliferation ( Fig. 2A) . In cocultures performed in the presence of ADA or ADA-Hg, it was observed that active and enzymatically inactive ADA promoted an increase in the percentage of T cells expressing CD45RO (Fig. 2B) , demonstrating that the deaminase activity was not required to potentiate the generation of Teffs. As it has been described previously that ADA, independently of its deami-nase activity, leads to a marked increase in the production of the Th1 and proimmflamatory cytokines IFN-␥, TNF-␣, and IL-6 [14] , the role of these cytokines in the ADA-induced increase in CD45RO and CD25 expression was investigated. Accordingly, naïve CD4
-T cells were cocultured with autologous, SEA-pulsed iDCs in the presence of ADA, IL-6, TNF-␣, IFN-␥, or a combination of these factors, and CD45RO and CD25 expression on T cells was determined by flow cytometry. The concentration of cytokines used for these experiments was equivalent to the average of the maximum amount of cytokines produced in this experimental setup in response to ADA [14] . As shown in Fig. 3A and C, IL-6 and to a lesser extent, TNF-␣ and IFN-␥ enhanced generation of Teffs. In magnitude, the IL-6-mediated effect was not significantly different from the ADA-mediated effect, and the maximum effect was obtained when using a cocktail of the three cytokines (Fig. 3A and C) or when using IL-6 plus TNF-␣ or IL-6 plus IFN-␥ (data not shown). In cocultures performed in the presence of ADA and activity-neutralizing antibodies directed against IL-6, TNF-␣, or IFN-␥, the ADA-induced effect was reduced significantly (Fig. 3B and D) , something that was not encountered when an irrelevant mouse IgG1 was used (data not shown). Neither CD45RO nor CD25 expression was modified significantly in cocultures performed in the presence of IL-6 and the anti-IL-6 antibody, TNF-␣ and the anti-TNF-␣ antibody, or IFN-␥ and the anti-IFN-␥ antibody (data not shown), which confirmed the neutralizing action of these antibodies. Overall, these results indicate that IL-6, TNF-␣, and IFN-␥ may be involved in the ADA-induced pathway, leading to the potentiation of Teff generation.
Taking into account that ADA induces a costimulatory effect by interacting with CD26 on the T cell surface and with A 2B R on the iDCs surface [14] , control experiments were performed to test whether the T cell-iDC interaction is able to modulate the expression of ADA and ADA-binding proteins. Results show that ADA expression on the T cell surface was increased by coculturing them with SEA-pulsed iDCs; the effect was slightly potentiated by IL-6 and by a cocktail of IL-6, TNF-␣, and IFN-␥ (Supplemental Fig. 1A) . It was also observed that the CD26 expression on the T cell surface was increased significantly when T cells were cocultured with SEA-pulsed iDCs, and this effect was also slightly potentiated by IL-6 and by a cocktail of IL-6, TNF-␣, and IFN-␥ but not by ADA (Supplemental Fig. 1B ). All CD4 ϩ T cells expressed A 2B R on the plasma membrane (Supplemental Fig. 1C) , and levels of this receptor increased when naïve T cells were cocultured with SEA-pulsed iDCs, as measured by the geometric mean value of fluorescence intensity. Neither ADA nor the cytokines described above were able to further increase A 2B R expression levels on CD4 ϩ T cells (Supplemental Fig. 1C and D) . 
ADA enhanced the generation of CD4
؉ CD45RO ؉
CD45RA -CD25 -memory T cells
To determine the effect of ADA upon memory T cell generation after effector responses, T cells with the memory phenotype CD4 ϩ CD45RO ϩ CD25 -were identified in cocultures of naïve CD4
ϩ CD45RA ϩ CD45RO -T cells and autologous, SEApulsed iDCs. The CD45RA expression in the CD4 ϩ CD25 -population decreased upon time (Fig. 4A, upper image) , and this CD45RA -population was confirmed to be CD45RO ϩ (Fig. 4A,  lower image) . Importantly, the presence of ADA induced a notable increase of memory T cells at Day 14 of coculture (Fig. 4A) . The ADA-mediated effect was observed in cells from almost every healthy or HIV-infected donor (Fig. 4B ) without significant differences when comparing HIV-infected and healthy individuals. Thus, the ADA induced enhancement of the Teff phenotype during the peak of T cell response results, after the contraction phase, in an increased generation of memory T cells.
To test whether the ADA enzymatic activity is involved in the ADA-induced increase of memory T cell generation, cocultures were performed in the presence of ADA or ADA-Hg. As shown in Fig. 4C , ADA and ADA-Hg promoted an increase in the percentage of CD45RO-expressing cells within the CD4 ϩ CD25 --gated population of T cells. These results indicate that ADA enzymatic activity was not required to enhance memory T cell generation and suggest that similarly to ADA-enhanced Teff generation, augmented memory T cell production is mediated by interaction of ADA with ADA-binding proteins. To investigate the role of IFN-␥, TNF-␣, and IL-6 on the ADA-induced increase of memory T cell generation, cocultures of naïve
CD4
ϩ CD45RA ϩ CD45RO -T cells and autologous, SEA-pulsed iDCs were performed in the absence or in the presence of ADA, IFN-␥, TNF-␣, or IL-6 and in the presence of a combination of these factors. As shown in Fig. 5A and B, IL-6 and to a lesser extent, IFN-␥ and TNF-␣ were able to emulate the ADA effect on the CD4 ϩ CD25 -CD45RO ϩ T cell generation. When the three cytokines were added together, an additive effect was observed. Moreover, when IL-6 was combined with IFN-␥ or TNF-␣, but not when TNF-␣ was combined with IFN-␥, a significant increase in the generation of memory CD4 ϩ T cells was reached (data not shown). In cocultures performed in the presence of ADA and neutralizing antibodies directed against IL-6, TNF-␣, or IFN-␥, the ADA-induced effect was reduced (Fig. 5C) , and it did not change in the presence of irrelevant mouse IgG1 (data not shown). As a negative control, the generation of memory CD4 ϩ T cells was not significantly modified in cocultures performed in the presence of IL-6 and the anti-IL-6 antibody, TNF-␣ and the anti-TNF-␣ antibody, or IFN-␥ and the anti-IFN-␥ antibody (data not shown). Taken together, these results indicate that mainly IL-6, and to a minor extent, IFN-␥ and TNF-␣ are involved in the ADA-promoted enhancement of the memory CD4 ϩ T cell generation. 
ADA enhanced the generation of CD4
Foxp3
ϩ T cells in cocultures from healthy and HIV-infected donors (Fig. 6A) . The effect was not significantly different on comparing HIV-infected patients and healthy controls. Controls performed using nonpulsed iDCs did not lead to the generation of the CD4 ϩ CD25 high
ϩ T cell phenotype, in the absence or in the presence of ADA (data not shown). Enzyme-inactive ADA (Fig. 6B ) was unable to potentiate the generation of CD4 T cells was analyzed in cocultures performed in the absence or in the presence of ADA or in the presence of IFN-␥, TNF-␣, IL-6, or a cocktail of these cytokines, the ADA-triggered increase of Treg production was not emulated (Fig. 7) . Therefore, the generation of Tregs seemed to be dependent on the enzymatic activity of ADA.
DISCUSSION
The lack of ADA is deleterious for the development and function of lymphocytes. The pathological mechanism linking ADA deficiency to SCID was first assumed to be largely dependent on dATP accumulation and toxicity [30] . AdoRs were placed into the equation later on, as excess of Ado as a result of an ADA deficit may lead to sustained activation of AdoRs present in lymphocytes [10, 31] . AdoR-mediated regulation of the immune system is mediated by at least three of the four receptor subtypes, A 2B [32, 33] , A 3 [34] , and A 2A [12, 35] . As we demonstrated that ADA was on the cell surface of lymphocytes [36, 37] , and cell surface ADA-binding proteins started to be identified [38 -41] , the enzyme-independent, signaling-dependent role of ADA on immune function has been demonstrated. Cell surface ADA may therefore contribute to lymphocyte development, activation, and fate by two mechanisms: by regulating the levels of extracellular Ado available to AdoRs and by interacting with ADA-binding proteins and engaging cAMP-independent signaling pathways. It is here shown that ADA-mediated costimulation, in a deaminase activity-independent way, promotes an enhanced production of Teffs during the effector phase of the T cell response and augmented generation of memory T cells after the effector phase. Furthermore, the enzymatic activity of ADA promotes an augmented generation of Tregs during the effector phase of the T cell response. Importantly, the potentiation in the induction of Teffs, Tregs, and memory T cells was not only observed in cocultures of cells obtained from healthy individuals but also in cultures of cells obtained from HIV-infected patients.
Cellular and molecular mechanisms involved in the generation of memory T cells are not yet well known. The findings here reported point to the idea that the intercellular A 2B R-ADA-CD26 interaction contributes to the differentiation from naïve CD4 ϩ CD45RA ϩ T cells toward memory CD4 ϩ CD45RO ϩ T cells. It has been demonstrated that CD26-triggered signaling occurs through its interaction with CD45 in the plasma membrane of T cells [42, 43] . When CD45RO anchors CD26 in lipid raft microdomains, CD26 engagement evokes stimulatory signals for T cell activation [42] ; in contrast, when CD45RA maintains CD26 excluded from lipid rafts, CD26 engagement attenuates T cell activation [43] . This evidence suggests that in our coculture conditions, the interaction of the A 2B R-ADA-CD26 complex with CD45RA would not, at first, promote any positive effect on the generation of Teffs and memory T cells. Indeed, no ADA-mediated increase of CD25 or CD45RO expression was observed at short incubation times (data not shown). In contrast, when the TCR-triggered switch of CD45RA to CD45RO is induced, the ADA-mediated effect would begin to operate positively in the production of Teffs and later, in the generation of memory T cells. CD39 and CD73 have been described as two surface markers specifically expressed on the Foxp3 ϩ population of CD4 ϩ T cells [44, 45] . The coordinated action of these two ecto-enzymes catalyzes the production of pericellular Ado from extracellular nucleotides. As a result of the inhibitory role of A 2A R stimulation in the activation and function of Teffs [11] [12] [13] , the synthesis of extracellular Ado by Tregs constitutes one of the regulatory mechanisms operating in these cells to attenuate Teff responses [44, 45] . In this regard, enhanced expression of ecto-ADA would enhance Ado degradation, thus leading to make Teffs less responsive to the inhibition exerted by Tregs. On the other hand, we observed here that ADA promoted an augmented generation of CD4 ϩ CD25 high Foxp3 ϩ Tregs by a mechanism that seemed to be mainly dependent on its enzymatic activity. This constitutes the first study reporting a regulatory role of Ado in the generation of Tregs. Therefore, it seems that the deaminase activity of ADA is involved in potentiating the generation of Tregs. Several studies have revealed a correlation among depletion of CD4 ϩ CD26 ϩ T cells, increased serum levels of ADA, and the evolution of AIDS in infected individuals [46 -48] . Furthermore, it has been described that ADA binding to CD26 is inhibited by soluble rHIV-1 envelope glycoprotein gp120 and by HIV-1 infectious particles [49] . Importantly, whereas ADA-CD26-mediated costimulation of T cell activation is impaired in HIV-1-infected patients [24] , we here show that ADA-mediated costimulation promotes potentiation in the generation of Teffs and memory T cells in a similar extent to that observed in cocultures from healthy individuals. Thereby, exogenous addition of ADA could increase effector response and generation of CD4 ϩ memory T cells against HIV. As ADA-mediated enhancement in the production of Teffs is followed by a delayed increase of Tregs, the addition of exogenous ADA to potentiate effector response seems to be a self-limited and promising approach to be used as a complement for immunostimulatory therapies. Another important point to consider is that whereas HIV-infected patients require potentiation of the Th1 reponse [25] , their T cell responses are often deviated toward Th2 [25] . We have described previously that ADA-mediated costimulation favors a Th1 pattern in CD4 ϩ T cells [14] . Thus, an ADA-based therapy could be beneficial for potentiation of Th1 effector responses and generation of immunological memory in HIV-infected individuals. In this regard, we have proposed recently that ADA would be a good adjuvant to be used in a DC-based vaccine for the treatment of AIDS [25] . Similarly, this idea could be applicable to potentiate an antitumor Th1 response in cancer patients.
The present results not only contribute to the knowledge of T cell biology but also provide a rationale for the development of therapeutic strategies aimed at reinforcing a compromised immune system. In fact, an imbalance between Teffs and Tregs has been observed in pathological scenarios ranging from immunosuppression [50, 51] and cancer [52] to autoimmunity [53, 54] . As a result of the fact that development of vaccines relies on the generation of memory T cells [55] , our results may also be useful in the formulation of novel vaccines or immunotherapies.
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